Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients
Journal
Diabetes Care
Journal Volume
25
Journal Issue
2
Pages
376-380
Date Issued
2002
Author(s)
Jeng C.-Y.
Wu T.-J.
Tanaka S.
Funahashi T.
Matsuzawa Y.
Wang J.-P.
Abstract
OBJECTIVE - Adiponectin, a plasma protein exclusively synthesized and secreted by adipose tissue, has recently been shown to have anti-inflammatory, antiatherogenic properties in vitro and beneficial metabolic effects in animals. Lower plasma levels of adiponectin have been documented in human subjects with metabolic syndrome and coronary artery disease. We investigated whether the level of this putative protective adipocytokine could be increased by treatment with a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist in diabetic patients. RESEARCH DESIGN AND METHODS - Type 2 diabetic patients (30 in the treatment group and 34 in the placebo group) were recruited for a randomized double-blind placebo-controlled trial for 6 months with the PPAR-γ agonist rosiglitazone. Blood samples were collected and metabolic variables and adiponectin levels were determined in all patients before initiation of the study. RESULTS - In the rosiglitazone group, mean plasma adiponectin level was increased by more than twofold (P < 0.0005), whereas no change was observed in the placebo group. Multivariate linear regression analysis showed that whether rosiglitazone was used was the single variable significantly related to the changes of plasma adiponectin. The amount of variance in changes of plasma adiponectin level explained by the treatment was ?24% (r2 = 0.24) after adjusting for age, sex, and changes in fasting plasma glucose, HbA1c, insulin resistance index, and BMI. CONCLUSIONS - Rosiglitazone increases plasma adiponectin levels in type 2 diabetic subjects. Whether this may contribute to the antihyperglycemic and putative antiatherogenic benefits of PPAR-γ agonists in type 2 diabetic patients warrants further investigation.
SDGs
Other Subjects
adiponectin; glucose; hemoglobin A1c; peroxisome proliferator activated receptor agonist; rosiglitazone; 2,4 thiazolidinedione derivative; adiponectin; antidiabetic agent; cell receptor; protein; rosiglitazone; signal peptide; thiazole derivative; transcription factor; article; blood sampling; body mass; clinical article; clinical trial; controlled clinical trial; controlled study; double blind procedure; female; glucose blood level; human; insulin resistance; linear regression analysis; male; non insulin dependent diabetes mellitus; protein blood level; randomized controlled trial; treatment outcome; adipose tissue; aged; blood; drug potentiation; metabolism; middle aged; multivariate analysis; phase 3 clinical trial; Adiponectin; Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multivariate Analysis; Proteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors
Type
journal article